KalVista Pharmaceuticals (KALV) Cash from Operations (QoQ) (2014 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -35.03% |
| Oct 31, 2024 | 1.44% |
| Jul 31, 2024 | -166.27% |
| Apr 30, 2024 | 45.21% |
| Jan 31, 2024 | -39.07% |
| Oct 31, 2023 | 25.83% |
| Jul 31, 2023 | -18.09% |
| Apr 30, 2023 | -143.69% |
| Jan 31, 2023 | 54.89% |
| Oct 31, 2022 | 9.45% |
| Jul 31, 2022 | 15.11% |
| Apr 30, 2022 | -90.47% |
| Jan 31, 2022 | 28.04% |
| Oct 31, 2021 | -10.21% |
| Jul 31, 2021 | -60.57% |
| Apr 30, 2021 | -45.60% |
| Jan 31, 2021 | 4.60% |
| Oct 31, 2020 | -121.63% |
| Jul 31, 2020 | 71.56% |
| Apr 30, 2020 | 3.75% |
| Jan 31, 2020 | -67.76% |
| Oct 31, 2019 | 30.70% |
| Jul 31, 2019 | -7.27% |
| Apr 30, 2019 | 3.18% |
| Jan 31, 2019 | -23.56% |
| Oct 31, 2018 | -41.44% |
| Jul 31, 2018 | -4.32% |
| Apr 30, 2018 | -121.10% |
| Jan 31, 2018 | 488.76% |
| Oct 31, 2017 | -63.20% |
| Jul 31, 2017 | -68.42% |
| Apr 30, 2017 | 76.51% |
| Jan 31, 2017 | -168.54% |
| Oct 31, 2016 | 25.96% |
| Mar 31, 2016 | -0.34% |
| Dec 31, 2015 | 4.50% |
| Sep 30, 2015 | 17.62% |
| Jun 30, 2015 | -59.08% |
| Sep 30, 2014 | -66.36% |
| Jun 30, 2014 | -10.49% |